+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2017-01-12Number of Pages: 188

Hemophilia Treatment Drugs Market (Product - Recombinant Coagulation Factor Concentrates, Plasma Derived Coagulation Factor Concentrates, Desmopressin, and Antifibrinolytic Agents; Disease Indication - Hemophilia A, Hemophilia B, Acquired Hemophilia, and Hemophilia C; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, and E-commerce) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024

Global Hemophilia Treatment Drugs Market: Overview

The global hemophilia treatment drugs market is presently catering to various sub-types of hemophilia such as hemophilia A, hemophilia B and others such as acquired hemophilia and hemophilia C. The increasing awareness of this disorder and the introduction of innovative ways of managing this disease has opened up several opportunities for the global market in recent years. According to the research report, the global hemophilia treatment drugs market was valued at US$15.8 bn in 2015 and is expected to reach US$25.1 bn in 2024, as the market is projected to progress at a CAGR of 5.4%.

The global market is also estimated to benefit from the several blockbuster drugs in the existing portfolio. Presently, these drugs are contributing to the major share of the revenue of the market. The introduction of new drugs and FDA approvals for clinical trials to launch blockbuster treatments is expected to drive this market in the coming years. The commercial availability of promising drugs is anticipated to change the way hemophilia is managed and treated for many patients during the forecast period.

hemophilia treatment drugs market

Recombinant Coagulation Factor Concentrates Lead Global Market due to Low Risk of Blood-borne Infections

On the basis of product, the global market is segmented into recombinant coagulation factor concentrates, desmopressin, plasma derived coagulation factor concentrates, and antifibrinolytic agents. Out of these products, the recombinant coagulation factor concentrates are expected to dominate the global market in the coming years. The growing preference of medical practitioners for these therapies due to low risk of blood borne infections is anticipated to drive this segment. In 2015, the recombinant coagulation factor concentrates segment held a share of 46.6% in the global market in terms of revenue. This segment is further divided into factor VIII, factor IX and combination drugs.

North America to Show Sustained Demand as Awareness about Disease Continues to Grow

In terms of geography, the global hemophilia treatment drugs market is categorized into Europe, Asia Pacific, North America, Latin America, and the Middle East and Africa. Out of these regions, North America has been leading the global market for a few decades and is expected to continue its stance in the coming years due to well-established healthcare infrastructure. Furthermore, the growing awareness about the disease in the region is also expected to boost sales of products in the coming years.  Currently, the U.S. is leading the hemophilia drugs market in North America.

On the other hand, Europe is anticipated to lose its share as several top-selling drug brands are experiencing patent cliff. Presently, the U.K is leading the Europe market. Asia Pacific is also anticipated to offer several lucrative opportunities to the overall market due to an exponentially growing demand for unmet medical needs. The rising per capita income, improving healthcare facilities, growing awareness about the disorder, and emerging economies of Asia Pacific have lent a significant impetus to the overall market. Additionally, increasing focus on treating bleeding disorders across Asia Pacific and Latin America are also expected give the overall market a remarkable boost in the coming few years.

Some of the key players operating in the global hemophilia treatment drugs market are Shire Plc, Biogen, Pfizer Inc., Novo Nordisk A/S, CSL Behring, F. Hoffmann-La Roche Ltd., Bayer AG, Biotest AG, Kedrion Biopharma Inc., and Octapharma AG. The competitive landscape of the global market can be described as a consolidated one with top ten players holding a mammoth share in the overall market in terms of revenue. Over the coming years, these companies are expected to show a keen interest in expanding their geographical reach and widening their presence in various parts of the world.

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Hemophilia Treatment Drug Market

4. Market Overview
     4.1. Introduction
            4.1.1. Product Type Definition
            4.1.2. Industry Evolution / Developments
     4.2. Overview
     4.3. Key Market Indicators
            4.3.1. Region/Country Specific
            4.3.2. Product/Application/By Distribution Channel Specific
            4.3.3. Target Market Specific – Global Scenario
     4.4. Market Dynamics
            4.4.1. Drivers
            4.4.2. Restraints
            4.4.3. Opportunity
     4.5. Global Hemophilia Treatment Drug Market Analysis and Forecasts, 2014–2024
            4.5.1. Market Revenue Projections (US$ Mn)
     4.6. Hemophilia Treatment Drug Market - Global Supply Demand Scenario
     4.7. Porter’s Five Force Analysis
     4.8. Value Chain Analysis
     4.9. Market Outlook

5. Global Hemophilia Treatment Drug Market Analysis and Forecasts, By Product Type
     5.1. Introduction & Definition
     5.2. Key Findings / Developments
     5.3. Key Trends
     5.4. Market Value Forecast By Product Type, 2014–2024
            5.4.1. Recombinant coagulation factor concentrates
                     5.4.1.1. Factor VIII
                     5.4.1.2. Factor IX
                     5.4.1.3. Combination
            5.4.2. Plasma derived coagulation factor concentrates
                     5.4.2.1. Factor VIII
                     5.4.2.2. Factor IX
                     5.4.2.3. Combination
            5.4.3. Desmopressin
            5.4.4. Antifibrinolytic agents
     5.5. Product Type Comparison Matrix
     5.6. Market Attractiveness By Product Type

6. Global Hemophilia Treatment Drug Market Analysis and Forecasts, By Disease Indication
     6.1. Introduction & Definition
     6.2. Key Findings / Developments
     6.3. Key Trends
     6.4. Market Value Forecast By Disease Indication, 2014–2024
            6.4.1. Hemophilia A
            6.4.2. Hemophilia B
            6.4.3. Others
     6.5. Disease Indication Comparison Matrix
     6.6. Market Attractiveness By Disease Indication

7. Global Hemophilia Treatment Drug Market Analysis and Forecasts, By Distribution
Channel

     7.1. Introduction & Definition
     7.2. Key Findings / Developments
     7.3. Key Trends
     7.4. Market Value Forecast By Distribution Channel, 2014–2024
            7.4.1. Hospital Pharmacies
            7.4.2. Retail Pharmacies
            7.4.3. E- commerce
     7.5. By Distribution Channel Comparison Matrix
     7.6. Market Attractiveness By Distribution Channel

8. Global Hemophilia Treatment Drug Market Analysis and Forecasts, By Region
     8.1. Key Findings
     8.2. Policies and Regulations
     8.3. Market Value Forecast By Region
            8.3.1. North America
            8.3.2. Europe
            8.3.3. Asia Pacific
            8.3.4. Latin America
            8.3.5. Middle East & Africa
     8.4. Market Attractiveness By Country/Region

9. North America Hemophilia Treatment Drug Market Analysis and Forecast
     9.1. Introduction
            9.1.1. Key Findings
     9.2. Market Value Forecast By Product Type, 2014–2024
            9.2.1. Recombinant coagulation factor concentrates
                     9.2.1.1. Factor VIII
                     9.2.1.2. Factor IX
                     9.2.1.3. Combination
            9.2.2. Plasma derived coagulation factor concentrates
                     9.2.2.1. Factor VIII
                     9.2.2.2. Factor IX
                     9.2.2.3. Combination
            9.2.3. Desmopressin
            9.2.4. Antifibrinolytic agents
     9.3. Market Value Forecast By Disease Indication, 2014–2024
            9.3.1. Hemophilia A
            9.3.2. Hemophilia B
            9.3.3. Others
     9.4. Market Value Forecast By Distribution Channel, 2014–2024
            9.4.1. Hospital Pharmacies
            9.4.2. Retail Pharmacies
            9.4.3. E- commerce
     9.5. Market Value Forecast By Country, 2014–2024
            9.5.1. U.S.
            9.5.2. Canada
     9.6. Market Attractiveness Analysis
            9.6.1. By Product Type
            9.6.2. By Disease Indication
            9.6.3. By Distribution Channel
            9.6.4. By Country

10. Europe Hemophilia Treatment Drug Market Analysis and Forecast
     10.1.Introduction
            10.1.1. Key Findings
     10.2.Market Value Forecast By Product Type, 2014–2024
            10.2.1. Recombinant coagulation factor concentrates
                     10.2.1.1. Factor VIII
                     10.2.1.2. Factor IX
                     10.2.1.3. Combination
            10.2.2. Plasma derived coagulation factor concentrates
                     10.2.2.1. Factor VIII
                     10.2.2.2. Factor IX
                     10.2.2.3. Combination
            10.2.3. Desmopressin
            10.2.4. Antifibrinolytic agents
     10.3.Market Value Forecast By Disease Indication, 2014–2024
            10.3.1. Hemophilia A
            10.3.2. Hemophilia B
            10.3.3. Others
     10.4.Market Value Forecast By Distribution Channel, 2014–2024
            10.4.1. Hospital Pharmacies
            10.4.2. Retail Pharmacies
            10.4.3. E- commerce
     10.5.Market Value Forecast By Country, 2014–2024
            10.5.1. Germany
            10.5.2. U.K.
            10.5.3. France
            10.5.4. Spain
            10.5.5. Italy
            10.5.6. Rest of Europe
     10.6.Market Attractiveness Analysis
            10.6.1. By Product Type
            10.6.2. By Disease Indication
            10.6.3. By Distribution Channel
            10.6.4. By Country

11. Asia Pacific Hemophilia Treatment Drug Market Analysis and Forecast
     11.1.Introduction
            11.1.1. Key Findings
     11.2.Market Value Forecast By Product Type, 2014–2024
            11.2.1. Recombinant coagulation factor concentrates
                     11.2.1.1. Factor VIII
                     11.2.1.2. Factor IX
                     11.2.1.3. Combination
            11.2.2. Plasma derived coagulation factor concentrates
                     11.2.2.1. Factor VIII
                     11.2.2.2. Factor IX
                     11.2.2.3. Combination
            11.2.3. Desmopressin
            11.2.4. Antifibrinolytic agents
     11.3.Market Value Forecast By Disease Indication, 2014–2024
            11.3.1. Hemophilia A
            11.3.2. Hemophilia B
            11.3.3. Others
     11.4.Market Value Forecast By Distribution Channel, 2014–2024
            11.4.1. Hospital Pharmacies
            11.4.2. Retail Pharmacies
            11.4.3. E- commerce
     11.5.Market Value Forecast By Country, 2014–2024
            11.5.1. Japan
            11.5.2. China
            11.5.3. Australia
            11.5.4. New Zealand
            11.5.5. India
            11.5.6. Rest of Asia Pacific
     11.6.Market Attractiveness Analysis
            11.6.1. By Product Type
            11.6.2. By Disease Indication
            11.6.3. By Distribution Channel
            11.6.4. By Country

12. Latin America Hemophilia Treatment Drug Market Analysis and Forecast
     12.1.Introduction
            12.1.1. Key Findings
     12.2.Market Value Forecast By Product Type, 2014–2024
            12.2.1. Recombinant coagulation factor concentrates
                     12.2.1.1. Factor VIII
                     12.2.1.2. Factor IX
                     12.2.1.3. Combination
            12.2.2. Plasma derived coagulation factor concentrates
                     12.2.2.1. Factor VIII
                     12.2.2.2. Factor IX
                     12.2.2.3. Combination
            12.2.3. Desmopressin
            12.2.4. Antifibrinolytic agents
     12.3.Market Value Forecast By Disease Indication, 2014–2024
            12.3.1. Hemophilia A
            12.3.2. Hemophilia B
            12.3.3. Others
     12.4.Market Value Forecast By Distribution Channel, 2014–2024
            12.4.1. Hospital Pharmacies
            12.4.2. Retail Pharmacies
            12.4.3. E- commerce
     12.5.Market Value Forecast By Country, 2014–2024
            12.5.1. Brazil
            12.5.2. Mexico
            12.5.3. Rest of Latin America
     12.6.Market Attractiveness Analysis
            12.6.1. By Product Type
            12.6.2. By Disease Indication
            12.6.3. By Distribution Channel
            12.6.4. By Country

13. Middle East & Africa Hemophilia Treatment Drug Market Analysis and Forecast
     13.1.Introduction
            13.1.1. Key Findings
     13.2.Market Value Forecast By Product Type, 2014–2024
            13.2.1. Recombinant coagulation factor concentrates
                     13.2.1.1. Factor VIII
                     13.2.1.2. Factor IX
                     13.2.1.3. Combination
            13.2.2. Plasma derived coagulation factor concentrates
                     13.2.2.1. Factor VIII
                     13.2.2.2. Factor IX
                     13.2.2.3. Combination
            13.2.3. Desmopressin
            13.2.4. Antifibrinolytic agents
     13.3.Market Value Forecast By Disease Indication, 2014–2024
            13.3.1. Hemophilia A
            13.3.2. Hemophilia B
            13.3.3. Others
     13.4.Market Value Forecast By Distribution Channel, 2014–2024
            13.4.1. Hospital Pharmacies
            13.4.2. Retail Pharmacies
            13.4.3. E- commerce
     13.5.Market Value Forecast By Country, 2014–2024
            13.5.1. South Africa
            13.5.2. UAE
            13.5.3. Saudi Arabia
            13.5.4. Rest of Middle East and Africa
     13.6.Market Attractiveness Analysis
            13.6.1. By Product Type
            13.6.2. By Disease Indication
            13.6.3. By Distribution Channel
            13.6.4. By Country

14. Competition Landscape
     14.1.Market Player – Competition Matrix (By Tier and Size of companies)
     14.2.Market Share Analysis By Company (2015)
     14.3.Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
            14.3.1. Pfizer, Inc.
                     14.3.1.1 Company Overview
                     14.3.1.2 Business Overview
                     14.3.1.3 Financial Overview
                     14.3.1.4 SWOT Analysis
                     14.3.1.5 Strategic Overview
            14.3.2. Biotest AG
                     14.3.2.1 Company Overview
                     14.3.2.2 Business Overview
                     14.3.2.3 Financial Overview
                     14.3.2.4 SWOT Analysis
                     14.3.2.5 Strategic Overview
            14.3.3. CSL Behring
                     14.3.3.1 Company Overview
                     14.3.3.2 Business Overview
                     14.3.3.3 Financial Overview
                     14.3.3.4 SWOT Analysis
                     14.3.3.5 Strategic Overview
            14.3.4. Kedrion
                     14.3.4.1 Company Overview
                     14.3.4.2 Business Overview
                     14.3.4.3 Financial Overview
                     14.3.4.4 SWOT Analysis
                     14.3.4.5 Strategic Overview
            14.3.5. Octapharma AG
                     14.3.5.1 Company Overview
                     14.3.5.2 Business Overview
                     14.3.5.3 Financial Overview
                     14.3.5.4 SWOT Analysis
                     14.3.5.5 Strategic Overview
            14.3.6. Shire Plc
                     14.3.6.1 Company Overview
                     14.3.6.2 Business Overview
                     14.3.6.3 Financial Overview
                     14.3.6.4 SWOT Analysis
                     14.3.6.5 Strategic Overview
            14.3.7. Novo Nordisk A/S
                     14.3.7.1 Company Overview
                     14.3.7.2 Business Overview
                     14.3.7.3 Financial Overview
                     14.3.7.4 SWOT Analysis
                     14.3.7.5 Strategic Overview
            14.3.8. Bayer AG
                     14.3.8.1 Company Overview
                     14.3.8.2 Business Overview
                     14.3.8.3 Financial Overview
                     14.3.8.4 SWOT Analysis
                     14.3.8.5 Strategic Overview
            14.3.9. F. Hoffmann-La Roche Ltd.
                     14.3.9.1 Company Overview
                     14.3.9.2 Business Overview
                     14.3.9.3 Financial Overview
                     14.3.9.4 SWOT Analysis
                     14.3.9.5 Strategic Overview
            14.3.10. Biogen
                     14.3.10.1 Company Overview
                     14.3.10.2 Business Overview
                     14.3.10.3 Financial Overview
                     14.3.10.4 SWOT Analysis
                     14.3.10.5 Strategic Overview

List of Figures

Figure 01: Global Hemophilia Treatment Drugs Market Value Share Analysis, by Product Type, 2016 and 2024
Figure 02: Global Recombinant Coagulation Factor Concentrates Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 03: Global Plasma Derived Coagulation Factor Concentrates Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 04: Global Desmopressin Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 05: Global Antifibrinolytic Agents Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 06: Global Hemophilia Treatment Drugs Market Value Share Analysis, by Disease Indication, 2016 and 2024
Figure 07: Global Hemophilia A Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 08: Global Hemophilia B Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 09: Global Others Market Revenue (US$ Mn) and
Figure 10: Global Hemophilia Treatment Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2024
Figure 11: Global Hospital Pharmacies Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 12: Global Retail Pharmacies Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 13: Global E-commerce Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 14: Global Hemophilia Treatment Drugs Market Value Share Analysis, by Region, 2016 and 2024
Figure 15: Hemophilia Treatment Drugs Market Attractiveness Analysis, by Region
Figure 16: North America Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2016–2024
Figure 17: North America Market Attractiveness Analysis, by Country
Figure 18: North America Market Value Share Analysis, by Product Type, 2016 and 2024
Figure 19: North America Market Value Share Analysis, by Disease Indication, 2016 and 2024
Figure 20: North America Market Value Share Analysis, by E Distribution Channel, 2016 and 2024
Figure 21: North America Market Value Share Analysis, by Country, 2016 and 2024
Figure 22: North America Market Attractiveness Analysis, by Product Type
Figure 23: North America Market Attractiveness Analysis, by Disease Indication
Figure 24: North America Market Attractiveness Analysis, by Distribution Channel
Figure 25: Europe Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, 2016–2024
Figure 26: Europe Market Attractiveness Analysis, by Country
Figure 27: Europe Market Value Share Analysis, by Product Type, 2016 and 2024
Figure 28: Europe Market Value Share Analysis, by Disease Indication, 2016 and 2024
Figure 29: Europe Market Value Share Analysis, by Distribution Channel, 2016 and 2024
Figure 30: Europe Market Value Share Analysis, by Country, 2016 and 2024
Figure 31: Europe Market Attractiveness Analysis, by Product Type
Figure 32: Europe Market Attractiveness Analysis, by Disease Indication
Figure 33: Europe Market Attractiveness Analysis, by Distribution Channel
Figure 34: Asia Pacific Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, 2016–2024
Figure 35: Asia Pacific Market Attractiveness Analysis, by Country
Figure 36: Asia Pacific Market Value Share Analysis, by Product Type, 2016 and 2024
Figure 37: Asia Pacific Market Value Share Analysis, by Disease Indication, 2016 and 2024
Figure 38: Asia Pacific Market Value Share Analysis, by Distribution Channel, 2016 and 2024
Figure 39: Asia Pacific Market Value Share Analysis, by Country, 2016 and 2024
Figure 40: Asia Pacific Market Attractiveness Analysis, by Product Type
Figure 41: Asia Pacific Market Attractiveness Analysis, by Disease Indication
Figure 42: Asia Pacific Market Attractiveness Analysis, by Distribution Channel
Figure 43: Latin America Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, 2016–2024
Figure 44: Latin America Market Attractiveness Analysis, by Country
Figure 45: Latin America Market Value Share Analysis, by Product Type, 2016 and 2024
Figure 46: Latin America Market Value Share Analysis, by Disease Indication, 2016 and 2024
Figure 47: Latin America Market Value Share Analysis, by Distribution Channel, 2016 and 2024
Figure 48: Latin America Market Value Share Analysis, by Country, 2016 and 2024
Figure 49: Latin America Market Attractiveness Analysis, by Product
Figure 50: Latin America Market Attractiveness Analysis, by Disease Indication
Figure 51: Latin America Market Attractiveness Analysis, by Distribution Channel
Figure 52: Middle East & Africa Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, 2016–2024
Figure 53: Middle East & Africa Market Attractiveness Analysis, by Country
Figure 54: Middle East & Africa Market Value Share Analysis, by Product Type, 2016 and 2024
Figure 55: Middle East & Africa Market Value Share Analysis, by Disease Indication, 2016 and 2024
Figure 56: Middle East & Africa Market Value Share Analysis, by Distribution Channel, 2016 and 2024
Figure 57: Middle East & Africa Market Value Share Analysis, by Country, 2016 and 2024
Figure 58: Middle East & Africa Market Attractiveness Analysis, by Product
Figure 59: Middle East & Africa Market Attractiveness Analysis, by Disease Indication
Figure 60: Middle East & Africa Market Attractiveness Analysis, by Distribution Channel
Figure 61: Global Hemophilia Treatment Drugs Market Share Analysis, by Company (2015)

List of Tables

Table 01: Global Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Product Type, 2016–2024
Table 02: Global Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Recombinant Coagulation Factor Concentrates, 2016–2024
Table 03: Global Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Plasma derived coagulation factor concentrates, 2016–2024
Table 04: Europe Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2016–2024
Table 05: Global Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2014–2024
Table 06: Global Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Region, 2016–2024
Table 07: North America Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Product Type, 2016–2024
Table 08: North America Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Recombinant coagulation factor concentrates, 2016–2024
Table 09: North America Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Plasma derived coagulation factor concentrates, 2016–2024
Table 10: North America Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2016–2024
Table 11: North America Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
Table 12: North America Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 13: Europe Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Product Type, 2016–2024
Table 14: Europe Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Recombinant coagulation factor concentrate, 2016–2024
Table 15: Europe Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Plasma derived coagulation factor concentrates, 2016–2024
Table 16: Europe Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2016–2024
Table 17: Europe Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
Table 18: Europe Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 19: Asia Pacific Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Product Type, 2016–2024
Table 20: Asia Pacific Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Recombinant coagulation factor concentrate, 2016–2024
Table 21: Asia Pacific Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Plasma derived coagulation factor concentrates, 2016–2024
Table 22: Asia Pacific Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2016–2024
Table 23: Asia Pacific Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
Table 24: Asia Pacific Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 25: Latin America Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Product Type, 2016–2024
Table 26: Latin America Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Recombinant coagulation factor concentrate, 2016–2024
Table 27: Latin America Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Plasma derived coagulation factor concentrates, 2016–2024
Table 28: Latin America Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2016–2024
Table 29: Latin America Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
Table 30: Latin America Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 31: Middle East & Africa Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Product Type, 2016–2024
Table 32: Middle East & Africa Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Recombinant coagulation factor concentrate, 2016–2024
Table 33: Middle East & Africa Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Plasma derived coagulation factor concentrates, 2016–2024
Table 34: Middle East & Africa Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2016–2024
Table 35: Middle East & Africa Hemophilia Treatment Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
Table 36: Middle East & Africa Hemophilia Treatment Drugs Size (US$ Mn) Forecast, by Country, 2016–2024

Global Hemophilia Treatment Drugs Market: Overview

Hemophilia is a rare blood disorder. Hemophilia is a combination of two Greek words that is haima (blood) and philia (affection). Hemophilia is a hereditary disorder, passed from parents to the child. Hemophilia is a bleeding disorder which causes excess bleeding and poor blood clotting. The people with hemophilia are generally known as hemophiliacs. There are two main type of hemophilia, hemophilia A and hemophilia B. Hemophilia A or classical hemophilia is the most common type of hemophilia, caused by lack of factor VIII in blood. Hemophilia B also known as Christmas disease, as it was firstly diagnosed in person named Steven Christmas. Hemophilia B is caused by lack of factor IX in blood. Other hemophilia are hemophilia C, Acquired Hemophilia etc. Hemophilia A & B is passed from mother to child, but hemophilia C is passed from both mother and father to child. This report analyzes the current and future prospects of the hemophilia treatment drugs market based on type of product, disease indication, distribution channel and geography.

Global Hemophilia Treatment Drugs Market: Research Methodology

The research is a combination of primary and secondary research, conducted for understanding and arriving at trends, used to forecast the expected revenue of the major radiography techniques in the near future. Primary research formed the bulk of our research efforts with information collected from in-depth interviews and discussions with a number of key industry experts and opinion leaders. Secondary research involved study of company websites, annual reports, press releases, investor presentations, analyst presentation and various international and national databases. The report provides estimated market size in terms of US$ Mn for each Product type, disease indication, distribution channel, and geography for the period 2015 to 2024, considering the macro and micro environmental factors. The revenue generated from each product was calculated by considering number of products used in the procedures and their market demand as per their use, number of product launched, average cost of products of each sub segment, trends in industry, end user trend, and adoption rate across all the geographies. The revenue generated for disease indication was calculated on the basis of prevalence of diseases in humans.

Global Hemophilia Treatment Drugs Market: Scope

The market report comprises an elaborated executive summary, which includes market snapshot that provides information about various segments of the market. It also provides information and data analysis of the market with respect to market segments based on type of product, disease indication, distribution channel and geography. The market overview section of the report analyzes market dynamics such as drivers, restraints and opportunities that influence the hemophilia treatment drugs market in the current and future scenario. The report also provides value chain analysis of the market that describes the sequence of activities involved from manufacturing to their final reach to the end users.

Global Hemophilia Treatment Drugs Market: Regional Outlook

Market share analysis among the market players is analyzed to signify percentage share of the major players operating in the market. All these factors will help the market players to decide about the business strategies and plans to strengthen their positions in the global market. Based on geography, the market has been analyzed for countries of North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Key Players Mentioned in the Report are:

The report also profiles the major players in the market and provides various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major companies profiled in the hemophilia treatment drugs market report are Novo Nordisk A/S, CSL Behring, F. Hoffmann-La Roche Ltd., Bayer AG, Pfizer Inc., Biotest AG, Kedrion Pharma, Inc., Octapharma AG, Shire Plc,  Biogen and some other players who are involved in the hemophilia treatment drugs market.

The global hemophilia treatment drugs market is segmented as follows:

Global Hemophilia Treatment Drugs Market Revenue, by Product type

  • Recombinant coagulation factor concentrates
    • Factor VIII
    • Factor IX
    • Combination
  • Plasma derived coagulation factor concentrates
    • Factor VIII
    • Factor IX
    • Combination
  • Desmopressin
  • Antifibrinolytic agents

Global Hemophilia Treatment Drugs Market Revenue, by Disease Indication

  • Hemophilia A
  • Hemophilia B
  • Others

Global Hemophilia Treatment Drugs Market Revenue, by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • E-commerce

Global Hemophilia Treatment Drugs Market Revenue, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • U.K.
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • Saudi Arabia
    • South Africa
    • Rest of Middle East & Africa


 
 
Back To Top